• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
water filter
WATER FILTER FOR WATER PURIFIER
DUST BAG
Small dust filter
HUMIDIFIER FILTER
Oil fume adsorption filter

Financial Report: PPD

contractpharmaOctober 30, 2020

Tag: PPD , Financial Report , revenues

PPD

3Q Revenues: $1.2 billion (+21%)

3Q Earnings: $9.1 million (-45%)

YTD Revenues: $3.3 billion (+11%)

YTD Earnings: $58.1 million (+69%)

Comments: Clinical Development Services revenue was $1.0 billion in the quarter, up 19% and Laboratory Services revenue was $225.2 million, up 27%. Net authorizations of $1.2 billion, representing 33% growth over third quarter 2019 and resulting in a net book-to-bill ratio of 1.35x on a historical basis. Ending backlog of $7.9 billion, representing 16% growth over third quarter 2019.

Previous:TherapeutAix Expands R&D Network

Next:Avomeen Names SVP of Lab Operations

Related News

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

PharmaSourcesOctober 15, 2024

Thrombolytic Science, LLC (TSI), announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for mutant prourokinase, a recombinant fibrinolytic pro-enzyme.

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

PharmaSourcesOctober 15, 2024

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

PharmaSourcesOctober 15, 2024

Financial Report: PPD | Pharmasources.com

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

PharmaSourcesOctober 15, 2024

BD and ten23 health today announced a collaboration to develop a new way to track prefillable syringes (PFS) using RFID technology.

You may like
More>>

P-PHENYL DIISOCYANATE（PPDI）99PCT

P-PHENYL DIISOCYANATE（PPDI）99PCT
P-PHENYLENE DIAMINE WHITE FLAKE (PPD)

P-PHENYLENE DIAMINE WHITE FLAKE (PPD)
P-phenylenediamine(PPD)Lump (106-50-3)

P-phenylenediamine(PPD)Lump (106-50-3)
2-NITRO-P-PHENYLENE DIAMINE SULFATE (2NPPDS)

2-NITRO-P-PHENYLENE DIAMINE SULFATE (2NPPDS)
2-Nitro-p-phenylene diamine（2NPPD）(5307-14-2)

2-Nitro-p-phenylene diamine（2NPPD）(5307-14-2)
P-phenylenediamine(PPD) (106-50-3)

P-phenylenediamine(PPD) (106-50-3)
P-PHENYLENE DIAMINE DIHYDROCHLORIDE (PPD-2HCL)

P-PHENYLENE DIAMINE DIHYDROCHLORIDE (PPD-2HCL)
Protopanaxadiol(APPD)-98%

Protopanaxadiol(APPD)-98%
2-NITRO-P-PHENYLENE DIAMINE (2NPPD)

2-NITRO-P-PHENYLENE DIAMINE (2NPPD)
Protopanaxadiol(APPD)-40%

Protopanaxadiol(APPD)-40%

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service